March 30, 2015 (Shareholders Foundation) - An investigation on behalf of investors of OHR Pharmaceutical Inc (NASDAQ:OHRP) shares over potential securities laws violations by OHR Pharmaceutical and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of OHR Pharmaceutical Inc (NASDAQ:OHRP) concerning whether a series of statements by OHR Pharmaceutical regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 27, 2015, OHR Pharmaceutical Inc announced the results of a mid-stage study of its lead drug, OHR-102. The study was designed to determine whether the drug could be used in tandem with the existing treatment, injectable eye drug Lucentis, to reduce the number of Lucentis injections patients required. But Ohr announced that there was no meaningful reduction in the number of injections required when OHR-102 was used, and that its study had thus failed its primary endpoint.

Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) declined from $9.97 per share on March 24, 2015, to as low as $2.72 per share on March 27, 2015.